Vancomycin resistance

Vancomycin is a glycopeptide antibiotic that acts by binding the bacterial cell envelope and inhibiting cell wall biosynthesis; the sources describe vancomycin resistance as a loss of this activity through specific bacterial resistance mechanisms ^[1][2]. In S. aureus, increased vancomycin resistance has been categorized as vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), with the latter defined in the source as complete resistance ^[1]. In enterococci, resistance to vancomycin is presented as one form of glycopeptide resistance among several acquired or intrinsic resistance patterns ^[4][3].

The source evidence links VISA to persistent infections, vancomycin treatment failure, and poor clinical outcomes ^[1]. For VRSA, the sources state that treatment is challenging, but they do not provide a broader clinical syndrome description beyond the resistance phenotype itself ^[1]. For enterococci with glycopeptide resistance, the cited material notes their association with severe infections such as endocarditis, meningitis, and septicaemia, but it does not specify which of these outcomes are attributable uniquely to vancomycin resistance rather than to enterococcal infection more generally ^[3]. Detailed symptom patterns, timing, and complication frequencies are not yet available from the supplied sources ^[1][3].

The provided sources describe vancomycin resistance as a clinically important problem in pathogenic species that are widely disseminated, with particular concern in healthcare and community settings for MRSA and in the healthcare environment for enterococci ^[1][2][4]. VISA was first discovered in the 1990s, while VRSA was first reported in the United States in 2002; the total number of human VRSA infections reported in the source is limited to 14 in the U.S. ^[1]. Enterococci are described as major causes of healthcare-associated infections and as well adapted to the healthcare environment because of their resilience under harsh conditions ^[4]. The sources do not provide population incidence, regional distribution beyond the U.S. VRSA report, or surveillance burden estimates for the broader syndrome ^[1][4].

The supplied material does not describe person-to-person transmission of vancomycin resistance as a standalone event. Instead, it characterizes resistance as emerging through bacterial evolution, stepwise mutation, or horizontal transfer of genetic elements, including plasmid-borne vanA-mediated resistance in VRSA ^[1][4]. In enterococci, resistance may be acquired or intrinsic, and genetic plasticity is highlighted as a mechanism supporting acquisition of vancomycin resistance ^[4][3].

The sources identify healthcare-associated settings as important contexts for enterococcal infection and note a high burden of MRSA in healthcare and community settings worldwide, but they do not provide a formal risk-group list for vancomycin resistance ^[1][4]. Based strictly on the supplied material, patients with severe Gram-positive infections treated with vancomycin, especially those involving MRSA or enterococci, are the clearest source-supported groups of concern ^[1][2]. Additional demographic or exposure-specific high-risk groups are not yet available from the cited snippets ^[1][4].

No direct prevention or infection-control recommendations are stated in the provided sources, so source-backed detail is not yet available ^[1][2][4]. The evidence does support a public-health rationale for limiting unnecessary glycopeptide exposure and for monitoring resistance patterns, because vancomycin is described as a drug of last resort and its clinical efficiency is threatened by disseminated resistance mechanisms ^[2]. The sources also suggest that surveillance of resistant phenotypes such as VISA and VRSA is important because these variants are associated with treatment failure or are rare but clinically challenging ^[1].

In surveillance, this entity should be read primarily as an antimicrobial resistance signal rather than as a single pathogen-specific disease syndrome ^[1][2]. The source evidence supports separating intermediate resistance from complete resistance in S. aureus, and distinguishing vancomycin resistance in enterococci from other glycopeptide resistance patterns ^[1][3]. Available source data are strongest for laboratory-defined resistance phenotypes and their clinical implications, while many operational details relevant to public-health monitoring, such as case definitions, routine reporting thresholds, and geographic burden, are not yet available ^[1][2][4].

1. 1 McGuinness WA et al. Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med. 2017 Jun. PMID: 28656013. PubMed: https://pubmed.ncbi.nlm.nih.gov/28656013/
2. 2 Stogios PJ et al. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020 Mar. PMID: 31899563. doi: 10.1002/pro.3819. PubMed: https://pubmed.ncbi.nlm.nih.gov/31899563/
3. 3 UPDATE ON VANCOMYCIN RESISTANCE. International Journal of Clinical Practice. 2000. doi: 10.1111/j.1742-1241.2000.tb11895.x. DOI: https://doi.org/10.1111/j.1742-1241.2000.tb11895.x
4. 4 García-Solache M et al. The Enterococcus: a Model of Adaptability to Its Environment. Clin Microbiol Rev. 2019 Mar 20. PMID: 30700430. doi: 10.1128/CMR.00058-18. PubMed: https://pubmed.ncbi.nlm.nih.gov/30700430/
5. 5 Vancomycin resistance. Inpharma Weekly. 1999. doi: 10.2165/00128413-199911900-00021. DOI: https://doi.org/10.2165/00128413-199911900-00021
6. 6 Vancomycin resistance. Trends in Microbiology. 1997. doi: 10.1016/s0966-842x(97)88838-5. DOI: https://doi.org/10.1016/s0966-842x(97)88838-5

ICD-10

ICD-11

Total cases

776

Peak month

2023-03

Coverage

1 reporting countries · 2012-09-14 → 2026-06-20